e-learning
resources
Virtual 2021
06.09.2021
Sleep across the lifespan in the new era of COVID - 19
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
PREVALENCE AND CHARACTERISTICS OF SAHS PATIENTS ADMITTED FOR COVID-19 PNEUMONIA
A. Urrutia Gajate (Bilbao (Bizkaia), Spain), S. Castro Quintas (Bilbao (Bizkaia), Spain), B. Gonzalez Quero (Bilbao (Bizkaia), Spain), L. Garcia Echeverria (Bilbao (Bizkaia), Spain), A. Gomez Larrauri (Bilbao (Bizkaia), Spain), V. Cabriada Nuño (Bilbao (Bizkaia), Spain)
Source:
Virtual Congress 2021 – Sleep across the lifespan in the new era of COVID - 19
Session:
Sleep across the lifespan in the new era of COVID - 19
Session type:
E-poster
Number:
2082
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Urrutia Gajate (Bilbao (Bizkaia), Spain), S. Castro Quintas (Bilbao (Bizkaia), Spain), B. Gonzalez Quero (Bilbao (Bizkaia), Spain), L. Garcia Echeverria (Bilbao (Bizkaia), Spain), A. Gomez Larrauri (Bilbao (Bizkaia), Spain), V. Cabriada Nuño (Bilbao (Bizkaia), Spain). PREVALENCE AND CHARACTERISTICS OF SAHS PATIENTS ADMITTED FOR COVID-19 PNEUMONIA. 2082
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
FOLLOW-UP OF PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND TORPID EVOLUTION
Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia
Year: 2021
IMMUNOLOGICAL EVENTS AND SURVIVAL IN LUNG CANCER PATIENTS WITH COPD
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020
FUNCTIONAL AND METABOLIC CHARACTERISTICS OF BRONCHOALVEOLAR LAVAGE FLUID CELLS IN PATIENTS WITH PROLONGED COMMUNITY ACQUIRED PNEUMONIA
Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Year: 2021
ONE YEAR MORTALITY IN PATIENTS WITH PNEUMOCOCCAL BACTERAEMIC COMMUNITY ACQUIRED PNEUMONIA: ROLE OF THREE PNEUMONIA SEVERITY SCORES
Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers
Year: 2017
SYSTEMIC EFFECT OF CONTINUOUS TREATMENT WITH AZITHROMYCYN IN PATIENTS WITH SEVERE COPD AND FREQUENT EXACERBATIONS
Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights
Year: 2019
A COMPARATIVE STUDY ON EFFECTS OF SUBSTANCE DEPENDENCE ON PULMONARY TUBERCULOSIS PATIENTS
Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities
Year: 2021
DIAGNOSTICS, THERAPY, COURSE AND RESULTS IN PATIENTS WITH CHRONIC EXTRINSIC ALLERGIC ALVEOLITIS.
Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children
Year: 2020
PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ADMITTED FOR PNEUMONIA ACQUIRED IN THE COMMUNITY.
Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis?
Year: 2020
LONG –TERM MORTALITY IN PATIENTS WITH PNEUMOCOCCAL AND LEGIONELLA PNEUMONIA
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
EXCESS MORTALITY IN PATIENTS WITH ASTHMA ON LONG-ACTING β2-AGONISTS
Source: Eur Respir J 2007; 29: 823
Year: 2007
EOSINOPHIL DISTRIBUTION AND DESCRIPTION IN A POPULATION COHORT OF ASTHMATIC PATIENTS
Source: International Congress 2019 – Clinical implications of asthma management
Year: 2019
RISK FACTORS FOR LONG-TERM MORTALITY IN PATIENTS WITH PNEUMOCOCCAL COMMUNITY-ACQUIRED PNEUMONIA
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
MAINTAINING PULMONARY REHABILITATION EFFECTS IN COPD PATIENTS AT HOME – A PROTOCOL STUDY
Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Year: 2020
EVALUATION OF OF SMALL AIRWAYS INFLAMMATORY PARAMETERS IN A GROUP OF ASTHMATIC PATIENTS
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
PHYSIOLOGICAL EFFECTS OF THREE DIFFERENT VENTILATORY MODES IN PATIENTS WITH OBESITY HYPOVENTILATION SYNDROME UNDER NOCTURNAL NONINVASIVE VENTILATION: A PILOT RANDOMIZED STUDY
Source: International Congress 2017 – Noninvasive ventilation for chronic respiratory failure
Year: 2017
EFFICACY OF IRON REPLETION WITHOUT ERYTHROPOIESIS-STIMULATING AGENT IN PATIENTS WITHCHEMOTHERAPY-INDUCED ANEMIA IN LUNG CANCER
Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement
Year: 2018
USEFULNESS OF MIRNAS AS PREDICTORS OF LUNG CANCER IN PATIENTS WITH COPD. A PILOT SUTDY
Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases
Year: 2021
PSYCHOLOGICAL FACTORS PREDICTIVE OF QUALITY OF LIFE IN PATIENTS WITH INTERSTITIAL PULMONARY DISEASE
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020
UTILITY OF BRONCHOALVEOLAR LAVAGE(BAL) TO DETECT INFECTIOUS COMPLICATIONS IN PATIENTS WITH SEVERE SARS-COV-2 PNEUMONIA
Source: Virtual Congress 2021 – COVID - 19 treatments
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept